The latest Novartis action to shutdown RNAi research based on:
"... the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move."
This contrasts with the EET and potential Phenomica progress in which:
- The delivery problem has been completely resolved;
- The targeting problem looks like it can be feasibly addressed; and
- The complex RNA payload against gene expression can be replaced with a simple payload against phenotype expression.
Compare the multiple billion$ directed to RNAi programmes - where Phylogica's tens of million$ actually has produced a significantly more effective platform.
PYC Price at posting:
3.4¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)